These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22450392)

  • 81. Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies.
    Rosenbloom J; Castro SV; Jimenez SA
    Ann Intern Med; 2010 Feb; 152(3):159-66. PubMed ID: 20124232
    [TBL] [Abstract][Full Text] [Related]  

  • 82. First-in-class antifibrotic therapy targeting type 1 lysophosphatidic acid receptor.
    Im DS
    Arch Pharm Res; 2012 Jun; 35(6):945-8. PubMed ID: 22870802
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Recent advances in the treatment of systemic sclerosis.
    Bournia VK; Vlachoyiannopoulos PG; Selmi C; Moutsopoulos HM; Gershwin ME
    Clin Rev Allergy Immunol; 2009 Jun; 36(2-3):176-200. PubMed ID: 19132559
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Ubiquitination in Scleroderma Fibrosis and Its Treatment.
    Long Y; Chen W; Du Q; Zuo X; Zhu H
    Front Immunol; 2018; 9():2383. PubMed ID: 30386338
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Antifibrotic Therapies: Where Are We Now?
    Yoon YJ; Friedman SL; Lee YA
    Semin Liver Dis; 2016 Feb; 36(1):87-98. PubMed ID: 26870935
    [TBL] [Abstract][Full Text] [Related]  

  • 86. T cells and B cells in the pathogenesis of systemic sclerosis: recent insights and therapeutic opportunities.
    Del Galdo F; Artlett CM
    Curr Rheumatol Rep; 2006 Apr; 8(2):123-30. PubMed ID: 16569371
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Recent advances in the diagnosis and treatment of systemic sclerosis.
    Kowal-Bielecka O; Bielecki M; Kowal K
    Pol Arch Med Wewn; 2013; 123(1-2):51-8. PubMed ID: 23344666
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Cytokines in the immunopathology of systemic sclerosis.
    Raja J; Denton CP
    Semin Immunopathol; 2015 Sep; 37(5):543-57. PubMed ID: 26152640
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Systemic Sclerosis Pathogenesis and Emerging Therapies, beyond the Fibroblast.
    Sierra-Sepúlveda A; Esquinca-González A; Benavides-Suárez SA; Sordo-Lima DE; Caballero-Islas AE; Cabral-Castañeda AR; Rodríguez-Reyna TS
    Biomed Res Int; 2019; 2019():4569826. PubMed ID: 30809542
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Protein Tyrosine Phosphatases in Systemic Sclerosis: Potential Pathogenic Players and Therapeutic Targets.
    Sacchetti C; Bottini N
    Curr Rheumatol Rep; 2017 May; 19(5):28. PubMed ID: 28397126
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Development of agents for the treatment of systemic sclerosis.
    Herrick AL
    Expert Opin Investig Drugs; 2001 Jul; 10(7):1255-64. PubMed ID: 11772249
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Metabolic perturbations in systemic sclerosis.
    O'Reilly S
    Curr Opin Rheumatol; 2022 Jan; 34(1):91-94. PubMed ID: 34636347
    [TBL] [Abstract][Full Text] [Related]  

  • 93. From mechanisms of action to therapeutic application: A review on current therapeutic approaches and future directions in systemic sclerosis.
    Del Papa N; Zaccara E
    Best Pract Res Clin Rheumatol; 2015 Dec; 29(6):756-69. PubMed ID: 27107511
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Lysophosphatidic acid-1-receptor targeting agents for fibrosis.
    Rancoule C; Pradère JP; Gonzalez J; Klein J; Valet P; Bascands JL; Schanstra JP; Saulnier-Blache JS
    Expert Opin Investig Drugs; 2011 May; 20(5):657-67. PubMed ID: 21434838
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Use of biologics and other novel therapies for the treatment of systemic sclerosis.
    Bruni C; Praino E; Allanore Y; Distler O; Gabrielli A; Iannone F; Matucci-Cerinic M
    Expert Rev Clin Immunol; 2017 May; 13(5):469-482. PubMed ID: 27899043
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Network-based modeling of drug effects on disease module in systemic sclerosis.
    Kim KJ; Moon SJ; Park KS; Tagkopoulos I
    Sci Rep; 2020 Aug; 10(1):13393. PubMed ID: 32770109
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Scleroderma therapy: clinical overview of current trends and future perspective.
    Topal AA; Dhurat RS
    Rheumatol Int; 2013 Jan; 33(1):1-18. PubMed ID: 23011088
    [TBL] [Abstract][Full Text] [Related]  

  • 98. New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.
    Lescoat A; Varga J; Matucci-Cerinic M; Khanna D
    Expert Opin Investig Drugs; 2021 Jun; 30(6):635-652. PubMed ID: 33909517
    [No Abstract]   [Full Text] [Related]  

  • 99. An update on recent randomized clinical trials in systemic sclerosis.
    Boleto G; Avouac J; Allanore Y
    Joint Bone Spine; 2021 Oct; 88(5):105184. PubMed ID: 33887472
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [Research progress in epigenetic studies on systemic sclerosis].
    Long Y; Chen W; Du Q; Zuo X; Zhu H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Dec; 43(12):1369-1375. PubMed ID: 30643055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.